Bristol-Myers Squibb Company (BMY) Dividends

Bristol-Myers Squibb offers a dividend yield of 4.20%, which is substantially higher than the broader market and generally attractive for income investors. The sustainability of this payout is supported by a strong Free Cash Flow (FCF) Yield of 10.7%. This indicates the company generates ample cash to cover the dividend, with a significant buffer. The dividend is also supported by a reasonable GAAP P/E of 17x, suggesting earnings are not excessively strained by the payout. However, a deeper look at the Quality Indicators from the framework reveals concerns. The balance sheet is a key weakness, with a Debt/Equity ratio of 2.44, far exceeding the framework's favourable threshold of low/zero debt (Debt/EBITDA < 1.0x). This high leverage introduces risk, especially in a rising interest rate environment. Furthermore, the company's Revenue Growth YoY is only 1.3%, which is not the consistent, double-digit growth the framework associates with high quality. This stagnation, coupled with looming patent expirations for key drugs, challenges the company's ability to grow the dividend meaningfully in the future. While the current payout is covered, the combination of high debt and low growth suggests the dividend profile is favourable only with caution, as the long-term trajectory depends on successful pipeline execution to improve the growth and balance sheet metrics. Analysis based on data as of 2024-05-15.